Pfizer starts Phase 2/3 study of oral antiviral drug for adults after COVID-19 exposure
Pfizer’s study will evaluate the investigational novel oral antiviral candidate PF-07321332 for the prevention of illness in adults living in the same household as someone with COVID-19.